Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborator: National Comprehensive Cancer Network
• Treatments: Fluorodeoxyglucose F18; Sunitinib

Criteria

Inclusion Criteria:- Measurable disease by RECIST criteria

• Pathologic diagnosis of renal cell cancer

• Advanced (stage IV) renal cell cancer

• Karnofsky performance status of (KPS>70)

• Consent to participate in the clinical trial Exclusion Criteria:- Patients who cannot complete a PET/CT scan.

• Pregnant women.

• Healthy volunteers.

• Patients participating in other research protocols will be excluded from this study.

• Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications for MRI.